BioVie Shares Rise 24% After FDA Approves Phase 2 Study
By Chris Wack
BioVie Inc. shares were up 24% to $6.75 after the company said
the U.S. Food and Drug Administration has authorized the company to
initiate a Phase 2 study assessing NE3107's potential pro-motoric
impact in Parkinson's disease patients.
The company said the NM201 study is a double-blind,
placebo-controlled, safety, tolerability, and pharmacokinetics
study in Parkinson's disease participants treated with
carbidopa/levodopa and NE3107 involving 40 patients.
The company has an active Phase 3 trial studying NE3107 in AD
that is expected to have topline results by the end of 2022.
The company expects to initiate patient enrollment for the NM201
study before the end of 2021. Topline results are expected by the
middle of 2022.
Volume for the stock was 160,000 shares at 1:15 p.m. ET,
compared to its 65-day average of 76,000 shares. The stock hit its
52-week low of $5.34 on Friday.
Write to Chris Wack at email@example.com
(END) Dow Jones Newswires
October 26, 2021 13:36 ET (17:36 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.